Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis
Go back to Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis| Regeneron (NASDAQ: REGN) | Delayed: 656.12 -6.97 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $663.09 | 52 Week High | $592.36 | |||
| Open | $658.00 | 52 Week Low | $325.35 | |||
| Day High | $663.10 | P/E | 172.21 | |||
| Day Low | $653.31 | EPS | $3.81 | |||
| Volume | 477,987 | |||||
| Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) | Delayed: 50.16 -0.34 (0.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.50 | 52 Week High | $35.13 | |||
| Open | $50.62 | 52 Week Low | $28.10 | |||
| Day High | $50.77 | P/E | N/A | |||
| Day Low | $50.10 | EPS | $0.00 | |||
| Volume | 2,274,356 | |||||
